The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, requires a complex several-stage synthetic process. Preliminary routes focused on protein section coupling, utilizing solid-phase production methodologies to build the long protein sequence. Subsequent investigation has explored different approaches, includi